$0.318
-0.060 (-18.79%)收盤時
- High
- 0.414
- Open
- 0.385
- VWAP
- 0.35
- Vol
- 4.37M
- Mkt Cap
- 6.02M
- Low
- 0.310
- Amount
- 1.52M
- EV/EBITDA, TTM
- 0.00
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Company’s rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.
估值指標
事件時間軸
資訊
8.503-03NewsfilterHepion Launches Next-Gen Liquid Biopsy Platform
- 5.006-25Newsfilter
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
5.006-16NASDAQ.COMHepion Pharmaceuticals Appoints Kaouthar Lbiati As Interim CEO
- 7.005-12NASDAQ.COM
Hepion Pharmaceuticals Initiates Transition to OTC Markets Following Nasdaq Delisting Notice
- 7.005-12Newsfilter
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
HEPA FAQ — answered by Alphio AI
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Company’s rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。